Jaclyn LoPiccolo, Ph.D., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nelfinavir | 4 | 2021 | 76 | 1.120 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 2 | 2017 | 77 | 0.710 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2018 | 247 | 0.610 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2019 | 274 | 0.560 |
Why?
|
| Prednisone | 1 | 2018 | 1546 | 0.480 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2017 | 2552 | 0.420 |
Why?
|
| Protein Multimerization | 1 | 2015 | 996 | 0.390 |
Why?
|
| GTP-Binding Protein beta Subunits | 2 | 2017 | 32 | 0.310 |
Why?
|
| GTP-Binding Protein gamma Subunits | 2 | 2017 | 31 | 0.300 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2007 | 107 | 0.300 |
Why?
|
| HIV Protease Inhibitors | 3 | 2014 | 436 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 11233 | 0.240 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2007 | 1159 | 0.200 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 5319 | 0.200 |
Why?
|
| Protein Kinases | 1 | 2007 | 1664 | 0.190 |
Why?
|
| Chloroquine | 1 | 2021 | 283 | 0.180 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 12530 | 0.180 |
Why?
|
| Pneumocystis carinii | 1 | 2018 | 72 | 0.170 |
Why?
|
| Pinocytosis | 1 | 2017 | 73 | 0.160 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2017 | 248 | 0.150 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 841 | 0.140 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2015 | 30 | 0.140 |
Why?
|
| rab5 GTP-Binding Proteins | 1 | 2015 | 50 | 0.140 |
Why?
|
| Protein Structure, Quaternary | 1 | 2015 | 449 | 0.130 |
Why?
|
| Antineoplastic Agents | 4 | 2014 | 13620 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2015 | 2938 | 0.120 |
Why?
|
| Administration, Oral | 2 | 2018 | 3951 | 0.120 |
Why?
|
| Bronchoscopy | 1 | 2018 | 846 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 3631 | 0.110 |
Why?
|
| Catalytic Domain | 1 | 2015 | 714 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 8886 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 715 | 0.110 |
Why?
|
| Protein Interaction Mapping | 1 | 2015 | 643 | 0.100 |
Why?
|
| Autophagy | 2 | 2007 | 1311 | 0.090 |
Why?
|
| Apoptosis | 2 | 2021 | 9962 | 0.090 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 16729 | 0.090 |
Why?
|
| Glucocorticoids | 1 | 2018 | 2104 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 3964 | 0.080 |
Why?
|
| Signal Transduction | 5 | 2017 | 23721 | 0.080 |
Why?
|
| Neoplasms | 3 | 2014 | 20514 | 0.070 |
Why?
|
| Genes, ras | 1 | 2009 | 706 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2021 | 10603 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 11194 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 5191 | 0.060 |
Why?
|
| Humans | 15 | 2021 | 715636 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2007 | 1828 | 0.060 |
Why?
|
| Liver | 1 | 2018 | 7588 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2017 | 4267 | 0.060 |
Why?
|
| Drug Design | 1 | 2007 | 1099 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 2023 | 0.050 |
Why?
|
| Endoplasmic Reticulum | 1 | 2007 | 1198 | 0.050 |
Why?
|
| Male | 6 | 2019 | 350156 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2007 | 2096 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 20338 | 0.040 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2017 | 171 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39334 | 0.040 |
Why?
|
| Adult | 4 | 2018 | 212228 | 0.040 |
Why?
|
| Lipids | 1 | 2007 | 3247 | 0.040 |
Why?
|
| Deuterium Exchange Measurement | 1 | 2015 | 35 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 2212 | 0.030 |
Why?
|
| Spodoptera | 1 | 2015 | 156 | 0.030 |
Why?
|
| Immobilized Proteins | 1 | 2015 | 25 | 0.030 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2015 | 87 | 0.030 |
Why?
|
| Guanosine Diphosphate | 1 | 2015 | 91 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2009 | 3043 | 0.030 |
Why?
|
| Lysophospholipids | 1 | 2017 | 328 | 0.030 |
Why?
|
| Peptides | 1 | 2007 | 4388 | 0.030 |
Why?
|
| Maryland | 1 | 2014 | 277 | 0.030 |
Why?
|
| Protein Binding | 2 | 2017 | 9559 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2014 | 903 | 0.030 |
Why?
|
| Animals | 6 | 2015 | 169277 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 7982 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2017 | 3818 | 0.030 |
Why?
|
| Aged | 3 | 2019 | 162383 | 0.020 |
Why?
|
| Middle Aged | 3 | 2019 | 214618 | 0.020 |
Why?
|
| Elongation Factor 2 Kinase | 1 | 2007 | 11 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 4907 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 2973 | 0.020 |
Why?
|
| Tobacco | 1 | 2009 | 412 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 5034 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2014 | 62037 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 6806 | 0.020 |
Why?
|
| Mutation | 1 | 2009 | 29270 | 0.020 |
Why?
|
| Caspases | 1 | 2007 | 948 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2009 | 1597 | 0.010 |
Why?
|
| Sirolimus | 1 | 2009 | 1560 | 0.010 |
Why?
|
| Time Factors | 2 | 2014 | 40892 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 6633 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 9848 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 58288 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 10513 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 11665 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 11138 | 0.010 |
Why?
|
| Mice | 2 | 2009 | 80320 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2007 | 19905 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 18185 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 56137 | 0.010 |
Why?
|
| Female | 3 | 2014 | 377052 | 0.000 |
Why?
|
| Prognosis | 1 | 2006 | 28987 | 0.000 |
Why?
|